US › Healthcare

Cellectar Biosciences Inc (CLRB)

US · Healthcare · Biotechnology

$1.14-4.20%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.9M

EPS

$-0.57

EPS estimate

$-0.55

EPS came in at -0.57 against a street estimate of -0.55 — a miss of 3.6%.

Key statistics

Market cap

$13.1M

Forward P/E

0.0

P/B

0.66

Book value

$3.62

EPS (TTM)

$-3.46

52-week high

$5.07

52-week low

$1.15

50-day MA

$2.27

200-day MA

$2.77

Beta

0.58

Analyst view

Analysts rate Cellectar Biosciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $11.50.

Shareholding

Insiders

1.75%

Institutions

34.71%

Largest institutional holders

Fund	Stake
Caligan Partners LP	4.97%
Nantahala Capital Management, LLC	4.66%
StemPoint Capital LP	3.76%
Vanguard Capital Management, LLC	3.46%
SILVERARC CAPITAL MANAGEMENT, LLC	3.40%
Bleichroeder LP	3.05%
Jupiter Topco LLC	2.90%
Balyasny Asset Management LLC	2.33%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cellectar Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.